Skip to content

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

Marion A.A. Libouban, Jeroen A.D.M. de Roos, Joost C.M. Uitdehaag, Nicole Willemsen-Seegers, Sara Mainardi, Jelle Dylus, Jos de Man, Bastiaan Tops, Jules P.P. Meijerink, Zuzana Storchová, Rogier C. Buijsman, René H. Medema, Guido J.R. Zaman. Oncotarget. 2017

15 August 2023|

Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity

Joost C.M. Uitdehaag, Jos de Man, Nicole Willemsen-Seegers, Martine B.W. Prinsen, Marion A.A. Libouban, Jan Gerard Sterrenburg, Joeri J.P. de Wit, Judith R.F. de Vetter, Jeroen A.D.M. de Roos, Rogier C. Buijsman and Guido J.R. Zaman. Journal of Molecular Biology. 2017

15 August 2023|

TTK Inhibitors as a Targeted Therapy for CTNNB1 (beta-catenin) Mutant Cancers

Guido J.R. Zaman, Jeroen A.D.M. de Roos, Marion A.A. Libouban, Martine B.W. Prinsen, Jos de Man, Rogier C. Buijsman, and Joost C.M. Uitdehaag. Molecular Cancer Therapeutics. 2017

15 August 2023|

Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model

A. R. R. Maia, J. de Man, U. Boon, A. Janssen, J.-Y. Song, M. Omerzu, J. G. Sterrenburg, M. B. W. Prinsen, N. Willemsen-Seegers, J. A. D. M. de Roos, A. M. van Doornmalen, J. C. M. Uitdehaag, G. J. P. L. Kops, J. Jonkers, R. C. Buijsman, G. J. R. Zaman and R. H. Medema. Annals of Oncology. 2015

15 August 2023|

A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets

Joost CM Uitdehaag, Folkert Verkaar, Husam Alwan, Jos de Man, Rogier C Buijsman and Guido JR Zaman. British Journal of Pharmacology. 2011

15 August 2023|

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0

Yvonne Grobben, Jos de Man, Antoon M. van Doornmalen, Michelle Muller, Nicole Willemsen-Seegers, Diep Vu-Pham, Winfried R. Mulder, Martine B. W. Prinsen, Joeri de Wit, Jan Gerard Sterrenburg, Freek van Cauter, Judith E. den Ouden, Anne M. van Altena, Leon F. Massuger, Joost C. M. Uitdehaag, Rogier C. Buijsman and Guido J. R. Zaman. Frontiers in Immunology. 2021

15 August 2023|
Previous12

info@crossfire-oncology.com

Privacy Policy
Disclaimer

Page load link
  • Crossfire Oncology
  • About us
  • Science
  • Pipeline
    • TTK/PLK1 inhibitor (BAL0891)
    • BTK inhibitor (CFON-026)
  • Working at Crossfire
  • News
  • Publications